Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PROVARIX · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | The first dose administered was VARIVAX(varicella vaccine manufactured by Merck) |
| Group 2 | EXPERIMENTAL | The first dose administered was VARILRIX(varicella vaccine manufactured by GSK) |
| Group 3 | EXPERIMENTAL | The first dose administered was SUDUVAX(varicella vaccine manufactured by GC Biopharma) |
| Group 4 | EXPERIMENTAL | The first dose administered was SKYVaricella(varicella vaccine manufactured by SK bioscience) |
| Group 5 | EXPERIMENTAL | The first dose administered was PROVARIX(varicella vaccine manufactured by Sinovac) |
| Name | Type | Description |
|---|---|---|
| PROVARIX | BIOLOGICAL | Participants will receive one dose (0.5 mL) of PROVARIX (VarV), a live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd., administered as the second dose of varicella vaccination. |
Inclusion Criteria: 1. Healthy children aged 15 months to 12 years. 2. Have received one dose of varicella vaccine at 12 months of age in Turkey (verified by vaccination card or official electronic immunization record). 3. Written informed consent obtained from parent(s) or legally authorized repre...
PROVARIX is a monoclonal antibody being developed for varicella, commonly known as chickenpox. It is intended for use in healthy children as part of a vaccination strategy, specifically as a second dose of varicella vaccine. The drug is currently in Phase 3 clinical development.
PROVARIX is being developed by Sinovac Biotech, Ltd, a biopharmaceutical company traded under the ticker SVA. The company is conducting a Phase 3 clinical trial for this varicella vaccine candidate in healthy children.
PROVARIX is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 3 trial is recruiting participants to evaluate the second dose of the varicella vaccine in healthy children.
PROVARIX is being studied in a Phase 3 clinical trial with the identifier NCT07475000, titled 'Second Dose of Varicella Vaccine in Healthy Children.' The trial is currently recruiting 300 participants in Turkey (Türkiye) and includes children aged 15 months and older.
PROVARIX is a varicella vaccine candidate, not a therapeutic monoclonal antibody. It is being developed to prevent chickenpox and is being tested as a second dose in healthy children. The drug is in Phase 3 trials and is not yet approved.